-
BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial
•
China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK). The partnership will initiate a global Phase I/II study to evaluate the safety and efficacy of BioCity’s BC3195 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) for patients with…
-
BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062
•
BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical study for its kidney disease drug SC0062 at the Guangdong Provincial People’s Hospital, the leading institution for the study. The study, named SUCCESS-01, aims to evaluate the efficacy and safety of SC0062 capsules in patients…
-
BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy
•
BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120 subjects in the Phase II clinical study for its small molecule ETA receptor antagonist, SC0062, in the IgA nephropathy cohort. The study, which first dosed in June 2023, marks a significant milestone in the development…
-
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
•
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to conduct a Phase Ib/II study assessing the safety and efficacy of BioCity’s BC3402 in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of advanced hepatocellular cell…
-
BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
•
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its cluster of differentiation-3 (CD3) epidermal growth factor receptor (EGFR)-targeted bispecific antibody (BsAb), BC3448. With this approval, the company will now initiate a Phase I…
